Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bisthianostat in Refractory or Recurrent Multiple Myeloma
NCT03618602Phase 1Unknown
- Sponsor
- Shanghai Theorion Pharmaceutical
- Start
- Apr 2018
- Primary completion
- Apr 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of bisthianostat in multiple myeloma (MM) (4 arms), sponsored by Shanghai Theorion Pharmaceutical. Primary endpoints: Maximum Tolerated Dose up to 24 months and Dose-Limiting Toxicity at 4 weeks. Status: unknown.
02
Drugs
bisthianostat
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT03618602.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03618602.